Parathyroid hormone and heart failure: novel biomarker strategy.
Heart failure (HF) is a clinical syndrome featuring cardiac pump failure along with signs and symptoms arising from salt and water retention mediated by activated renin-angiotensin-aldosterone system (RAAS). In addition to this cardiorenal perspective, HF is accompanied by a systemic illness, especially in advanced stages characterized by oxidative stress in various tissues, causing damage to soft tissue and bone. Secondary hyperparathyroidism (SHPT) which is also considered to contribute this systemic illness is therefore prominent in advanced HF. SHPT in HF occurs as a result of RAAS activation, prominent hyperaldosteronism, loop diuretic usage and decreased calcitriol level, all of which results in calcium excretion. We review the evidence that high parathyroid hormone (PTH) is associated with advanced HF, as well as evidence that it's associated with HF with preserved ejection fraction (HFPEF).
Department of Cardiology, Baskent University Faculty of Medicine, Oymacı Sk. No:7, 34662 Altunizade, Istanbul, Turkey. sakaltay@yahoo.com
Hakan
H
Altay
Yucel
Y
Colkesen
D015415:Biomarkers / Q000032:analysis*; D006333:Heart Failure / Q000175:diagnosis* / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D006961:Hyperparathyroidism / Q000150:complications / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000502:physiology*; D012307:Risk Factors; D013318:Stroke Volume
D015415:Biomarkers; D010281:Parathyroid Hormone